Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 11/18/24
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/13/24
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business HighlightsGlobeNewsWire • 11/13/24
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC ConferenceGlobeNewsWire • 11/04/24
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AMLGlobeNewsWire • 11/01/24
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research ForumGlobeNewsWire • 10/10/24
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/20/24
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024GlobeNewsWire • 09/14/24
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024GlobeNewsWire • 09/11/24
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung CancerGlobeNewsWire • 08/22/24
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/13/24
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesGlobeNewsWire • 08/13/24
VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipelinePRNewsWire • 06/03/24
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesGlobeNewsWire • 05/13/24
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 05/13/24
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 TrialGlobeNewsWire • 04/30/24
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For InvestorsSeeking Alpha • 04/05/24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumorsGlobeNewsWire • 04/02/24
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass EstimatesZacks Investment Research • 03/25/24
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated MilestonesGlobeNewsWire • 03/25/24
Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 03/21/24
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?Zacks Investment Research • 02/28/24